Kemp Dolliver
Stock Analyst at Brookline Capital
(0.55)
# 3,811
Out of 4,786 analysts
17
Total ratings
33.33%
Success rate
-15.3%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $4.43 | +283.75% | 1 | Dec 5, 2024 | |
| EYEN Eyenovia | Downgrades: Hold | n/a | $1.10 | - | 2 | Nov 15, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $0.44 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $4.02 | -10.45% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.89 | +1,145.67% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.22 | +2,473.77% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $0.28 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $97.60 | +2.46% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.44 | +2,236.07% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $2.70 | +825.93% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.69 | +180.27% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.95 | +740.25% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $1.18 | +380.56% | 1 | Feb 2, 2022 |
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $4.43
Upside: +283.75%
Eyenovia
Nov 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.10
Upside: -
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.44
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $4.02
Upside: -10.45%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.89
Upside: +1,145.67%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.22
Upside: +2,473.77%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.28
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $97.60
Upside: +2.46%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.44
Upside: +2,236.07%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.70
Upside: +825.93%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $6.69
Upside: +180.27%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.95
Upside: +740.25%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $1.18
Upside: +380.56%